Last reviewed · How we verify
NCT05808582
Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer
Phase 2 trial testing chidamide，fulvestrant in Hormone Receptor-positive Advanced Breast Cancer in 60 participants. Status unknown.
1 September 2023
Quick facts
| Lead sponsor | The First Affiliated Hospital with Nanjing Medical University |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 May 2023 |
| Primary completion | 1 September 2023 |
| Estimated completion | 1 September 2024 |
Drugs / interventions tested
- chidamide，fulvestrant
Conditions studied
- Hormone Receptor-positive Advanced Breast Cancer — all drugs for Hormone Receptor-positive Advanced Breast Cancer →
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Who can join
18 and older, female only, with Hormone Receptor-positive Advanced Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
evaluate the efficacy and safety of chidamide combined with fulvestrant for HR+ABC
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Epigenetic Therapies in Endocrine-Related Cancers: Past Insights and Clinical Progress.
Varun D, Haque M, Jackson-Oxley J, Thompson R, et al · · 2025 · cited 1× · PMID 40805121 · DOI 10.3390/cancers17152418
Verify or expand the search:
- PubMed search for NCT05808582
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The First Affiliated Hospital with Nanjing Medical University trials
Trials by the same sponsor.
- NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
- NCT07523789 — Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC · not yet recruiting
- NCT07464756 — SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer · Phase 2 · not yet recruiting
- NCT07482826 — Full-Endoscopic Decompression vs. Endoscopic Lumbar Fusion for Middle-Aged and Older Adults With Spinal Stenosis · NA · not yet recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05808582 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital with Nanjing Medical University
- Last refreshed: 14 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05808582.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing